Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Assets (2016 - 2025)

Historic Return on Assets for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 0.07%.

  • Protalix BioTherapeutics' Return on Assets rose 1900.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.04% for FY2024, which is 400.0% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Return on Assets is 0.07%, which was up 1900.0% from 0.08% recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Return on Assets high stood at 0.09% for Q3 2023, and its period low was 0.36% during Q4 2021.
  • Its 5-year average for Return on Assets is 0.11%, with a median of 0.16% in 2024.
  • In the last 5 years, Protalix BioTherapeutics' Return on Assets crashed by -2600bps in 2021 and then soared by 3900bps in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Return on Assets stood at 0.36% in 2021, then increased by 29bps to 0.26% in 2022, then skyrocketed by 124bps to 0.06% in 2023, then decreased by -28bps to 0.04% in 2024, then soared by 56bps to 0.07% in 2025.
  • Its last three reported values are 0.07% in Q3 2025, 0.08% for Q2 2025, and 0.05% during Q1 2025.